Ace Alzheimer Center Barcelona, present at CTAD 2022

Members of the management of Ace Alzheimer Center Barcelona have attended the 15th edition of the prestigious international Clinical Trials on Alzheimer's Disease (CTAD) conference, which was held in San Francisco from November 29 to December 2.

Dr. Boada, medical director and co-founder of Ace, Miren Jone Gurrutxaga, general director, Agustín Ruiz, research director, and Xavier Morató, head of clinical trials, have been the representatives of Ace at CTAD 2022. During the congress, the results of the study of the new drug Lecanemab, which included the participation of Ace in the clinical trial, have been presented.

The CTAD is a leading international meeting to discuss and present the latest progresses and trends in the research of new treatments for Alzheimer's disease.

You might also like

A new drug for Alzheimer's could reach the market in 2023

The pharmaceutical companies Eisai and Biogen have just announced to the press the results of their monoclonal antibody Lecanemab, a drug targeted at the deposit of amyloid in the brain.